Drugs Classification Quiz Related

Review Drugs Classification Quiz related questions and content

A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by the body may lead to:

  • A. Decreased effectiveness of irinotecan in the treatment of cancer
  • B. Increased adverse drug reactions, such as neutropenia
  • C. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
  • D. Increased concerns for irinotecan being carcinogenic
Correct Answer: B

Rationale: UGT1A1 mutations slow SN-38 inactivation, raising neutropenia risk , not affecting efficacy or activation .